论文部分内容阅读
目的探讨含有IQ模体的Ras GTP酶活化蛋白1(IQGAP1)在肝细胞肝癌组织中的表达及其临床意义。方法收集2007~2009年期间在笔者所在医院行肝癌切除治疗的79例肝细胞肝癌患者的临床资料,采用免疫组化法检测肝癌组织中IQGAP1的表达,并分析其与肝癌患者临床病理特征的关系,比较IQGAP1表达阳性和阴性患者肝癌切除术后的累积无瘤生存率及总体生存率。结果本组79例肝癌患者中肝癌组织中IQGAP1表达阳性者43(54.4%),IQGAP1表达阳性的患者多为低分化及存在微血管侵犯者。IQGAP1表达阳性与阴性患者术后1、3及5年的累积无瘤生存率分别为67.4%、39.5%及23.3%和100%、94.4%及83.3%,前者明显低于后者(P<0.001);IQGAP1表达阳性患者术后1、3及5年的累积总体生存率为97.7%、71.5%和53.3%,明显低于IQGAP1表达阴性者的100%、97.2%和88.9%(P<0.001)。结论肝细胞肝癌患者中IQGAP1阳性表达者预后较差。IQGAP1可能是肝细胞肝癌预后的指标。
Objective To investigate the expression of Ras GTPase-1 (IQGAP1) in the hepatocellular carcinoma and its clinical significance. Methods The clinical data of 79 patients with hepatocellular carcinoma who underwent resection of liver cancer in our hospital from 2007 to 2009 were collected. The expression of IQGAP1 in hepatocellular carcinoma was detected by immunohistochemistry and the relationship between IQGAP1 and the clinicopathological features of hepatocellular carcinoma The cumulative tumor-free survival and overall survival after HCC resection in patients with positive and negative IQGAP1 expression were compared. Results Of the 79 patients with HCC, IQGAP1 was found in 43 (54.4%) of the HCC patients. Most of the patients with positive IQGAP1 expression were poorly differentiated and had microvascular invasion. The cumulative tumor-free survival rates at 1, 3, and 5 years postoperatively in IQGAP1 positive and negative patients were 67.4%, 39.5%, 23.3% and 100%, 94.4% and 83.3% respectively, the former being significantly lower than the latter (P <0.001) ). The cumulative overall survival rates of patients with positive IQGAP1 expression at 1, 3 and 5 years after operation were 97.7%, 71.5% and 53.3%, which were significantly lower than those of IQGAP1-negative patients (100%, 97.2% and 88.9%, P <0.001) . Conclusion The prognosis of IQGAP1 positive patients with hepatocellular carcinoma is poor. IQGAP1 may be an indicator of the prognosis of hepatocellular carcinoma.